Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Naloxone Model OTC Label Expected From US FDA As Part Of Opioids Strategy

Executive Summary

US FDA Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees meet in December to discuss proposed routes to make the opioid overdose reversal agent naloxone more available: both as an OTC product and one co-prescribed with opioids.

You may also be interested in...



OTC Switch For Naloxone Finding Interest Among Sponsors

With FDA 'si label comprehension study near completion, sponsors seem more positive about OTC versions of naloxone products. FDA has made clear it is interested in switching the product from Rx-only but had trouble generating sponsor desire to develop it.

OTC Switch For Naloxone Finding Interest Among Sponsors

Now that US FDA is about to complete label comprehension study, sponsors seem more positive about OTC versions of naloxone products.

Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority

US FDA Commissioner says mandate for unit-of-dose packaging for opioids coming soon, but also acknowledges that move may make the drugs more expensive.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel